ACADIA Pharmaceuticals

Yahoo Finance • 8 days ago

Acadia raises 2025 NUPLAZID guidance to $665M–$690M as DAYBUE accelerates community uptake

Earnings Call Insights: ACADIA Pharmaceuticals (ACAD) Q2 2025 MANAGEMENT VIEW * Catherine E. Owen Adams, CEO, stated that "Our second quarter performance reinforces the momentum we're building across all facets of our business from com... Full story

Yahoo Finance • 8 days ago

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD [https://www.chartmill.com/stock/quote/ACAD/profile]) REPORTS Q2 2025 EARNINGS: REVENUE GROWTH MEETS EXPECTATIONS, EPS BEATS ESTIMATES Acadia Pharmaceuticals Inc. released its second-quarter 2025 fi... Full story

Yahoo Finance • 8 days ago

Here are the major earnings after the close Wednesday

Major earnings expected after the bell on Wednesday include: * Realty Income Corporation (O [https://seekingalpha.com/symbol/O]) * Energy Transfer LP (ET [https://seekingalpha.com/symbol/ET]) * Occidental Petroleum Corporation (OXY... Full story

Yahoo Finance • 9 days ago

S&P Futures Gain With Focus on Earnings and Fed Speak

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are trending up +0.24% this morning as investors digested U.S. President Donald Trump’s latest tariff threats and weak economic data, while shifting t... Full story

Yahoo Finance • 10 days ago

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

SAN DIEGO, August 04, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia’s dig... Full story

Yahoo Finance • 15 days ago

High Growth Tech Stocks in the US for July 2025

In the last week, the market has been flat, but it is up 16% over the past year with earnings forecast to grow by 15% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that are w... Full story

Yahoo Finance • 16 days ago

High Growth Tech Stocks in the US Market July 2025

Over the last 7 days, the United States market has remained flat, yet it has shown a robust performance with a 17% increase over the past year and earnings forecasted to grow by 15% annually. In this environment of steady growth, identifyi... Full story

Yahoo Finance • 21 days ago

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A High-Growth Biotech Stock with Fair Valuation

Investors looking for growth opportunities at fair prices often consider the "Affordable Growth" strategy, which focuses on companies with strong growth potential but without extreme overvaluation. This method selects stocks with a growth... Full story

Yahoo Finance • last month

ACADIA Pharmaceuticals' SWOT analysis: stock poised for growth amid pipeline expansion

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company specializing in central nervous system (CNS) disorders, is navigating a critical phase of growth and expansion. With a robust product portfolio and an ambitious pipeli... Full story

Yahoo Finance • 2 months ago

Acadia Pharmaceuticals stock maintains outperform rating at BMO Capital

Investing.com - BMO Capital reiterated its Outperform rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ:ACAD), currently trading at $22.50 with a market capitalization of $3.77 billion, following the company’s research and d... Full story

Yahoo Finance • 2 months ago

Acadia Pharmaceuticals stock rating reiterated by Canaccord on pipeline

Investing.com - Canaccord Genuity reiterated its Buy rating and $32.00 price target on Acadia Pharmaceuticals (NASDAQ:ACAD) following the company’s inaugural R&D Day held Wednesday. The research firm expressed increased conviction that th... Full story

Yahoo Finance • 2 months ago

Catalyst Watch: Powell goes to DC, FedEx earnings, and big banks get a stress test

[manhattan office building] franckreporter/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices ne... Full story

Yahoo Finance • 2 months ago

Macquarie initiates Neuren Pharmaceuticals stock with outperform rating

Macquarie initiated coverage on Neuren Pharmaceuticals Ltd (ASX:NEU) with an outperform rating and a price target of AUD18.60, according to a research note released Wednesday. The firm highlighted Neuren’s partnership with Acadia as a key... Full story

Yahoo Finance • 2 months ago

Acadia gets court approval related to Nuplazid patent

[Male Judge In A Courtroom Typing On Laptop] AndreyPopov/iStock via Getty Images * Acadia Pharmaceuticals (NASDAQ:ACAD [https://seekingalpha.com/symbol/ACAD]) said on Monday that the U.S. Court of Appeals upheld a December 2023 ruling,... Full story

Yahoo Finance • 3 months ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

SAN DIEGO, May 27, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acad... Full story

Yahoo Finance • 3 months ago

Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday

We recently published a list of 10 Surprising Stocks That Skyrocketed Today. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other Friday’s top performers. The stock market fi... Full story

Yahoo Finance • 3 months ago

Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on the shares. The firm sees the Delaware court’s verdict in favor of Acadia as consistent with its expectations for Nup... Full story

Yahoo Finance • 3 months ago

Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital

BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD) in their Nuplazid patent infringement lawsuit with Aurobindo, confirming today that Aurobindo infringed on claims... Full story

Yahoo Finance • 6 months ago

Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shareholders are probably feeling a little disappointed, since its shares fell 4.7% to US$19.34 in the week after its latest annual results. Revenues were US$958m, approximately in line with whatth... Full story

Yahoo Finance • last year

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

SAN DIEGO, August 07, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at 10:... Full story